Mozambique Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position

Sign up to download the Mozambique Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Mozambique Pharmaceuticals & Healthcare Report
Product Price

BMI View: The Mozambican government ' s focus on improving healthcare quality and access along with country ' s growing chronic disease burden will be the main driving factor for growth in the pharmaceutical and healthcare market. However, elevated tensions between political parties, weak intellectual property protection and poor regulatory environment make Mozambique an unattractive market for multinational drugmakers.

Headline Expenditure Forecasts

  • Pharmaceuticals: MZN7.59bn (USD242mn) in 2014 to MZN8.28bn (USD215mn) in 2015; +9.0% in local currency and -11.2% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: MZN34.99bn (USD1.12bn) in 2014 to MZN38.89bn (USD1.01bn) in 2015; +11.1% in local currency and -9.5% in US dollar terms. Forecast in line with last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Mozambique 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.220 0.242 0.215 0.208 0.227 0.251 0.270
Pharmaceutical sales, % of GDP 1.43 1.43 1.43 1.37 1.26 1.13 1.04
Pharmaceutical sales, % of health expenditure 21.2 21.7 21.3 21.0 20.6 20.2 20.1
Health spending, USDbn 1.038 1.116 1.010 0.989 1.099 1.238 1.346

Risk/Reward Index

Mozambique has scored 27.6 out of 100 - just below Cote d'Ivoire (28.1) - in our Pharmaceutical Risk/Reward Index (RRI) for Q116, marking a fall in last quarter's score of 29.5. The country is ranked the 26th most attractive pharmaceutical market in the Middle East and Africa (MEA) region.

Key Trends And Developments

  • In September 2015, Resolve Capacity secured a tender from the US Agency for International Development (USAID) to design and build a regional pharmaceutical warehouse in Nampula, Mozambique, with a budget of USD7.6mn.

  • In August 2015, Mozambique's health ministry introduced an updated list of essential medicines for 2015, aiming to reduce drug prices and increase availability. The revamped list contains over 400 drugs, of which 90 are new.

  • The Mozambique's health ministry is expected to launch three new vaccines for protection against intestinal problems, polio and measles in children.

BMI Economic View

Mozambique's economy will be hit by the global commodity price retreat via stalled investment in the country's burgeoning natural gas sector while constrained government spending will limit opportunities to prop up growth.

BMI Political View

Political risk will remain elevated in Mozambique in the coming year with an escalation of tensions between the ruling FRELIMO and opposition RENAMO party likely to result in an increasing number of violent events.

BMI Industry View
Operational Risk
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2011-2019)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2011-2019)
Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
Economic Analysis
Table: Economic Activity (Mozambique 2010-2019)
Industry Risk Reward Ratings
Middle East and Africa Risk/Reward Index - Q4 2015
Mozambique Risk/Reward Index
Market Overview
Industry Trends And Developments
Clinical Trials
Regulatory Development
Regulatory Development
Intellectual Property Issues
Pricing Regime
Competitive Landscape
Domestic Industry
Company Developments
Company Profile
Sociedade Mo-ambicana de Medicamentos (SMM)
Demographic Forecast
Table: Population Headline Indicators (Mozambique 1990-2025)
Table: Key Population Ratios (Mozambique 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Mozambique 1990-2025)
Table: Population By Age Group (Mozambique 1990-2025)
Table: Population By Age Group % (Mozambique 1990-2025)
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

The Mozambique Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mozambique Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mozambique pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Mozambique, to test other views - a key input for successful budgeting and strategic business planning in the Mozambican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mozambican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mozambique.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.